인플루엔자 치료제 시장 : 약제 유형, 인플루엔자 유형, 연령층, 투여 경로, 종류, 약제, 유통 채널, 세계 예측(2024-2032년)

Influenza Medications Market size is projected to witness 2.9% CAGR between 2024 and 2032, owing to increasing incidences of influenza infections worldwide. As per WHO, every year, approximately 1 billion cases of seasonal influenza occur, with 3-5 million instances categorized as severe illness. With the expanding global population, the spread of influenza viruses is becoming more prevalent, further imposing the need for effective medications to manage and treat the illness. The rising awareness among healthcare professionals and patients about the importance of early diagnosis and treatment of influenza will fuel the product demand.

Lately, there have been continuous efforts to develop new antiviral drugs with enhanced efficacy and fewer side effects, along with the introduction of innovative drug delivery methods, such as intravenous and intranasal formulations. The development of vaccines targeting different strains of influenza viruses and the adoption of vaccination campaigns by governments and healthcare organizations for reducing the incidence and severity of influenza infections will also stimulate the market growth.

The influenza medications industry is classified into drug type, influenza type, age group, route of administration, type, medication, distribution channel and region.

Based on route of administration, the market share from the intravenous segment is slated to record 1.3% growth rate during 2024-2032, due to its ability to deliver medications directly into the bloodstream while ensuring rapid and efficient absorption of the drug. This route of administration is particularly advantageous in cases of severe influenza infections or when oral medications are not feasible as it ensures immediate and targeted treatment. IV administration also enables healthcare professionals to closely monitor the patient's response to the medication and adjust the dosage as needed for enhancing treatment outcomes and reducing the risk of complications.

As per distribution channel, the influenza medications market from the online pharmacies segment will grow at 4.5% CAGR through 2032, backed by their convenience, accessibility, and cost-effectiveness. With the increasing reliance on digital platforms for healthcare needs, consumers are turning to online pharmacies to purchase influenza medications from the comfort of their homes. The ability to compare prices, access a wide range of products, and receive doorstep delivery within a short timeframe makes online pharmacies an attractive option for individuals seeking timely treatment for influenza symptoms.

Asia Pacific influenza medications industry is expected to generate lucrative opportunities and expand at a 3.6% CAGR from 2024-2032. This can be attributed to the increasing awareness and proactive measures taken by governments and healthcare organizations to combat influenza outbreaks, particularly in densely populated countries, such as China and India. The rise in healthcare infrastructure development, coupled with advancements in medical technology and drug manufacturing capabilities will further propel the market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of influenza
    • 3.2.1.2 Rising awareness and adoption of influenza medications
    • 3.2.1.3 Increasing research and development activities related to influenza drugs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with antiviral drugs
    • 3.2.2.2 High cost associated with drug development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antiviral drugs
  • 5.2.1 Single antiviral drugs
  • 5.2.2 Combination antiviral drugs
• 5.3 Antihistamines
• 5.4 Analgesics
• 5.5 Antipyretics

Chapter 6 Market Estimates and Forecast, By Influenza Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Influenza A
• 6.3 Influenza B

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Adults
• 7.3 Pediatric
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Inhaled
• 8.4 Intravenous

Chapter 9 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Branded
• 9.3 Generic

Chapter 10 Market Estimates and Forecast, By Medication, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Prescription
• 10.3 OTC

Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 Hospital pharmacies
• 11.3 Retail pharmacies
• 11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 Japan
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 Rest of Asia Pacific
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Rest of Latin America
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 Rest of Middle East and Africa

Chapter 13 Company Profiles

• 13.1 AstraZeneca plc
• 13.2 BioCryst Pharmaceuticals, Inc.
• 13.3 Daiichi Sankyo Company
• 13.4 F. Hoffmann-La Roche AG
• 13.5 GlaxoSmithKline plc
• 13.6 Lupin
• 13.7 NATCO Pharma Limited
• 13.8 Novartis AG
• 13.9 Sanofi
• 13.10 Teva Pharmaceutical Industries Ltd.